Author: Tom Wilemon
Jun. 18, 2019—A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work
Jun. 13, 2019—More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.
Jun. 13, 2019—Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).
Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
Jun. 6, 2019—Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.
May. 3, 2019—Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman’s risk for developing lymphedema.
Apr. 22, 2019—The varying roles that signaling molecules play in progression of cancer is the focus of the Vanderbilt-Ingram Cancer Center 20th Annual Scientific Retreat when some of the nation’s top experts will speak about “Signal Transduction in Cancer Initiation, Progression and Treatment.”
Apr. 18, 2019—Serving a region that lies within the tobacco belt, clinicians at Vanderbilt Health face challenges distinguishing lung cancer from histoplasmosis, a fungal infection that creates cancer-mimicking lesions in the lungs.
Apr. 11, 2019—When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.
Apr. 4, 2019—Early diagnosis of head and neck cancer greatly increases odds of survival, but its symptoms can be subtle or mimic viral infections, so Vanderbilt Health offers a free screening annually.